spacer
home > white papers > Choosing the Right CMO for HPAPI Manufacturing - AMRI
WHITE PAPERS
logo_AMRI4.jpg

AMRI

phone +1 1-518-512-2000
email info@amriglobal.com
web http://www.amriglobal.com
email 26 Corporate Circle, PO box 15098, Albany NY

Choosing the Right CMO for HPAPI Manufacturing

Over the past few years a steady stream of contract manufacturing organizations (CMO) have added high potency active pharmaceutical ingredient (HPAPI) production capacity. The expansions give biopharma executives charged with selecting HPAPI production partners an unprecedented number of options, but all this choice creates a problem — which CMO should you pick when each is touting similar technical capabilities?
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

rfxcel Covers the Cost of EMVO Onboarding Fees

May 23, 2018 - San Ramon, CA – rfxcel Corporation, a technically certified Gateway Provider for the European Medicines Verification Organisation (EMVO) announced today that it will pay the cost of statutory fees payable to EMVO* for all manufacturers (Marketing Authorisation Holders, MAHs) which select rfxcel as their Gateway Provider before June 15th 2018.
More info >>


White Papers

Case Study: Getting the Client’s Trust - Oncology Program

Cmed Clinical Services

Five years ago, a biopharmaceutical company chose Cmed to conduct a phase II oncology study. Cmed’s performance of the study and the good relationship established with the Client led Cmed to be awarded a second oncology trial which a couple of years ago was followed by a third, fourth and fifth.
More info >>


Industry Events

Automatica 2018

18 June 2018, Messe München, Munich, Germany

Automatica is the leading exhibition for smart automation and robotics. It features the world's largest range of robotics, assembly systems, machine vision systems and components. For more information go to automatic-munich.com/visitors
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement